Rivaroxaban in Patients with ACS: Do the Data Provide Support? - C. Michael Gibson, MD

↳ This is a section part of Moment: CRT 2016 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

C michael gibson2

Summary

Rivaroxaban in Patients with ACS: Do the Data Provide Support? presented by C. Michael Gibson, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management
Loading Simple Education